Results 21 to 30 of about 54,207 (313)

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

New England Journal of Medicine, 2020
BACKGROUND Outcomes in patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have improved with the use of tyrosine kinase inhibitors. Molecular remission is a primary goal of treatment.
R. Foà, R. Bassan, A. Vitale, L. Elia, A. Piciocchi, M. Puzzolo, M. Canichella, P. Viero, F. Ferrara, M. Lunghi, F. Fabbiano, M. Bonifacio, N. Fracchiolla, P. Di Bartolomeo, A. Mancino, M. D. De Propris, M. Vignetti, A. Guarini, A. Rambaldi, S. Chiaretti   +19 more
semanticscholar   +1 more source

Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia

Haematologica, 2023
Dasatinib is a multi-kinase inhibitor with activity against the SRC kinase LCK, which plays a critical role in T-cell receptor signaling. Dasatinib, initially developed as an immunosuppressive agent, is by contrast, also noted to result in enhanced ...
Patrick Harrington, Richard Dillon, Deepti Radia, Philippe Rousselot, Donal P. McLornan, Mark Ong, Anna Green, Alessandro Verde, Farzana Hussain, Kavita Raj, Shahram Kordasti, Claire Harrison, Hugues de Lavallade   +12 more
doaj   +1 more source

Dasatinib for treatment of CAR T-cell therapy-related complications

Journal for ImmunoTherapy of Cancer, 2022
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are severe, potentially life-threatening side effects of chimeric antigen receptor T-cell (CAR T) therapy caused by the release of cytokines by ...
K. Baur, D. Heim, Astrid Beerlage, Anna S Poerings, Bastian Kopp, M. Medinger, Jan Dirks, J. Passweg, A. Holbro   +8 more
semanticscholar   +1 more source

Dasatinib Nanoemulsion and Nanocrystal for Enhanced Oral Drug Delivery

Pharmaceutics, 2022
In this work, dasatinib (DAS) nanoemulsion and nanocrystal are produced by high-gravity technology that approaches to practical mass production. The drug nanoformulations were systematically characterized and evaluated.
Chuan-Qiang Wang, Manting Wang, Peng Chen, Jie-xin Wang, Yuan Le   +4 more
semanticscholar   +1 more source

Haemorrhagic Colitis Caused by Dasatinib [PDF]

Case Reports in Hematology, 2012
Gastrointestinal bleeding appears to be a common adverse event associated with dasatinib therapy. Here we present a case of a 59-year-old man with chronic myeloid leukaemia (CML) developing the rarest complication of haemorrhagic colitis with dasatinib therapy which resolved rapidly after treatment withdrawal.
Nidhi M. Sagar, Zbigniew Rudzki, Naveen Sharma, Gerald Langman, Nishant Patodi   +4 more
openaire   +4 more sources

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

Haematologica, 2013
Dasatinib is effective in most chronic phase chronic myeloid leukemia patients both in first-line therapy and following imatinib failure. While imatinib uptake into CD34+ cells is low compared to mononuclear cells, few data evaluate how well dasatinib ...
Devendra K. Hiwase, Verity A. Saunders, Eva Nievergall, Douglas D. Ross, Deborah L. White, Timothy P. Hughes   +5 more
doaj   +1 more source

Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review

Therapeutic Advances in Respiratory Disease, 2022
Dasatinib, a tyrosine kinase inhibitor, is usually prescribed for chronic myeloid leukemia and Philadelphia chromosome–positive acute lymphoblastic leukemia. However, some patients may develop an intolerance to this drug over the years.
Sang-A Kim, Byoung Soo Kwon, Jin-Haeng Chung, Ji Yun Lee, Soo-Mee Bang, Jeong-Ok Lee   +5 more
doaj   +1 more source

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]

, 2012
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Badura, Susanne, Khateb, Mamduh, Mahajna, Jamal, Metodieva, Anna, Mian, Afsar Ali, Najajreh, Yousef, Ottmann, Oliver Gerhard, Ruimi, Nili, Ruthardt, Martin   +8 more
core   +1 more source

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. [PDF]

, 2019
Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance or ...
Abruzzese, Elisabetta, Cortes, Jorge E, Hochhaus, Andreas, Hughes, Timothy P, Laneuville, Pierre, Lipton, Jeffrey H, Paar, David, Rea, Delphine, Rousselot, Philippe, Shah, Neil P, Snyder, David S   +10 more
core   +2 more sources

Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer. [PDF]

, 2014
Somatic mutations of the epidermal growth factor receptor often cause resistance to therapy with tyrosine kinase inhibitor in non-small cell lung cancer (NSCLC). In this study, we aimed to identify partner drugs and pathways that can induce cell death in
Koeffler, H Phillip, Leong, Geraldine, Madan, Vikas, Mori, Seiichi, Sudo, Makoto, Yang, Henry   +5 more
core   +5 more sources